This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trovagene Launches Easier Test For HPV Infection

By LINDA A. JOHNSON

TRENTON, N.J. (AP) â¿¿ Shares of Trovagene Inc. jumped Wednesday after the maker of molecular disease-detecting tests launched its new urine-based test for a common, sexually transmitted virus that can cause cervical cancer, some other cancer types and genital warts.

Trovagene said the HPV High Risk test looks for 15 different strains of human papilloma virus most likely to cause disease. It involves sophisticated genetic testing of a urine sample to detect snippets of DNA from those 15 strains, all of which can cause cervical cancer, but not genital warts.

The virus, called HPV for short, is the most common sexually transmitted one in the country. About 14 million people are infected each year, and 80 percent of all women are exposed to HPV at some point. According to the Centers for Disease Control and Prevention, HPV lurks in an estimated 79 million American women and men, most of whom don't know it.

That's because there is no general HPV test, there's none approved for some of the diseases it can cause and most women getting a routine Pap smear don't get a separate test for HPV at the same time.

The U.S. Preventive Services Task Force, aiming to increase awareness and limit spread of HPV, last year recommended that DNA testing for HPV infection be a mandatory part of women's screenings for cervical cancer.

Both those tests involve an uncomfortable procedure in which a metal instrument is inserted in the vagina to collect cells from the cervix. With a Pap smear, the cells are analyzed for the presence of cancer or pre-cancerous changes, while the HPV test looks for the virus itself.

San Diego-based Trovagene said its product might help overcome roadblocks to widespread testing for HPV, namely the cost, inconvenience and resistance of some patients to the invasive collection of cells from the cervix.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,094.01 +7.38 0.04%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs